How Pfizer Inc. Makes Money

Pfizer's ability to set premium pricing in the United States — where pharmaceutical pricing is largely unregulated compared to European reference pricing systems — is therefore central to overall profitability. The Inflation Reduction Act of 2022, which for the first time authorizes Medicare to negotiate drug prices directly with manufacturers, represents a structural change to this pricing model that Pfizer and its peers are still quantifying in terms of long-term revenue impact. The Inflation Reduction Act's Medicare drug price negotiation provisions directly threaten pricing power on several Pfizer products, including Eliquis, which was among the first ten drugs selected for negotiation. Internationally, reference pricing systems in Europe and government procurement leverage in emerging markets continue to compress net realized prices on Pfizer's portfolio. Public scrutiny of pharmaceutical pricing practices — which intensified during the COVID-19 pandemic when Pfizer's commercial success from government-funded vaccine development became a political flashpoint — has sustained pressure on the company's pricing and communications strategy. By formulating santonin with almond toffee to mask its bitter taste, Pfizer created one of the early examples of what we would today call a value-added pharmaceutical formulation — the active ingredient combined with delivery mechanisms designed to improve patient compliance.

The Seagen deal represented Pfizer's most explicit bet yet that oncology, not infectious disease, would define its next chapter of growth. For American investors, patients, policymakers, and anyone interested in how large corporations navigate the intersection of science, capital, and public health expectations, Pfizer's trajectory offers a uniquely instructive case study. Whether it can engineer another sustained growth cycle through oncology innovation, rare disease expansion, and next-generation vaccines remains the defining question of its current strategic era. Understanding how Pfizer actually makes money requires examining four distinct but interconnected revenue mechanisms: branded small molecule drugs, biologics and large-molecule therapies, vaccines, and the emerging antibody-drug conjugate oncology platform it acquired through Seagen. Oncology has become Pfizer's most strategically important growth segment following the Seagen acquisition. This modality represents one of the fastest-growing technology platforms in oncology, and Pfizer's Seagen acquisition positioned it alongside AstraZeneca-Daiichi Sankyo as the dominant force in the space. The rapid decline of Paxlovid revenues illustrates the fundamental volatility embedded in pandemic-related revenue streams and the critical importance of Pfizer's diversification strategy beyond COVID products. The company's R&D productivity — measured by the ratio of successful drug approvals to total development spending — has historically been below industry benchmarks, a chronic challenge that has driven repeated restructuring of research operations and therapeutic focus areas. The manufacturing network also creates substantial fixed cost structure that requires sustained revenue throughput to remain efficient, which partially explains why Pfizer has historically preferred large acquisitions over organic R&D alone as a growth mechanism. While Pfizer has been managing post-COVID revenue normalization and absorbing the Seagen acquisition, Eli Lilly has experienced a historically unusual pharmaceutical growth trajectory driven by tirzepatide (Mounjaro/Zepbound) and dulaglutide in the GLP-1 receptor agonist therapeutic area. The contrast is instructive: both companies are large-cap pharmaceutical manufacturers with substantial R&D investment, but their portfolio mix and pipeline timing have produced dramatically different investor outcomes in the early 2020s. The company's danuglipron oral GLP-1 program was discontinued in late 2023 due to adverse event profile concerns, a setback that eliminated what might have been a significant late-stage pipeline asset in the highest-growth category in medicine. Its Vyndaqel/Vyndamax franchise for transthyretin amyloid cardiomyopathy (ATTR-CM) has faced growing competition from Alnylam Pharmaceuticals' Onpattro and Amvuttra, which use RNA interference technology to reduce TTR protein production rather than stabilizing misfolded TTR as Pfizer's approach does. Through its Upjohn division spin-off in 2020 — which merged with Mylan to form Viatris — Pfizer exited the off-patent generics business, sharpening its competitive focus on patented branded pharmaceuticals and biologics. In aggregate, Pfizer's management has acknowledged that products representing approximately $17-18 billion in annual revenues face loss of exclusivity between 2025 and 2030, creating a revenue gap that the company's internal pipeline and acquired assets must collectively bridge. Pfizer paid a substantial premium for Seagen, implying aggressive growth expectations for the ADC platform that will require successful late-stage clinical trial readouts and commercial execution to justify. The company has successfully navigated FDA and EMA approval processes for hundreds of drug products over more than seven decades, building institutional knowledge about study design, data presentation, and regulatory negotiation that meaningfully increases the probability of successful approval for late-stage pipeline compounds. Third, Pfizer's global commercial infrastructure — its network of sales forces, medical affairs teams, market access specialists, and distribution relationships across more than 125 countries — creates a deployment platform for new products that smaller companies must either build from scratch or access through partnership. Pfizer's growth strategy for the period 2025-2030 rests on four interconnected pillars designed to rebuild revenue momentum following the post-pandemic contraction. The first and most immediate pillar is maximizing value from the Seagen oncology portfolio through label expansions, combination therapy approvals, and geographic market launches in Japan, China, and emerging market territories where Seagen's commercial footprint was limited prior to the acquisition. Pfizer's commercial infrastructure in these markets — already established through its branded pharmaceutical and vaccine businesses — provides the distribution platform to accelerate Seagen product uptake without the overhead of building new commercial organizations. Pfizer's gene therapy ambitions, built on the 2016 acquisition of Bamboo Therapeutics and subsequent platform development, represent a potentially transformational but still scientifically uncertain long-term growth avenue. The $4 billion cost reduction program announced in 2023 and the subsequent $1.5 billion additional savings initiative are designed to maintain competitive margins while revenue recovers, creating financial capacity for continued R&D investment without proportional overhead growth. The fourth pillar is maintaining and growing the dividend, which at approximately $1.68 per share annually remains a critical component of the investment thesis for Pfizer's large retail and institutional income-oriented shareholder base. The dividend's sustainability depends on free cash flow generation consistently exceeding capital requirements — a bar that Pfizer's management is under sustained investor scrutiny to clear. Clinical trial data from ongoing Phase 3 studies in multiple tumor types through 2025-2027 will be pivotal in determining whether the Seagen investment creates the expected value. In 1849, with $2,500 borrowed from Pfizer's father — a sum equivalent to roughly $90,000 in 2024 dollars — the two cousins established Charles Pfizer and Company in a red brick building on Bartlett Street in Brooklyn. The santonin business was modestly successful, but Pfizer's decisive early growth came from an entirely different product category: citric acid. Pfizer's fermentation technology — derived from the same biological science used in drug compound production — allowed domestic production at scale for the first time, rapidly expanding revenues and establishing manufacturing processes that would prove strategically critical a century later.